Evidence map›Paper›PMID 41550694›Full record

ArticleOpen forum infectious diseases2026

Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years.

Andrea Calcagno, Caterina Candela, Agostino Riva, Stefano Calza, Benedetta Fioretti, Samuele Gardini, Jovana Milic, Benedetto Maurizio Celesia, Giancarlo Orofino, Andrea De Vito and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Andrea CalcagnoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy.ORCID https://orcid.org/0000-0003-2534-8815
Caterina CandelaInfectious Disease Unit, Università Vita Salute San Raffaele, Milano, Italy.
Agostino RivaDepartment of Infectious Diseases, University of Milan, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Stefano CalzaUnit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Benedetta FiorettiDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Samuele GardiniInfectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
Jovana MilicDepartment of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0002-9806-8470
Benedetto Maurizio CelesiaDivision of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy.
Giancarlo OrofinoUnit of Infectious Diseases, "Divisione A", ASL "Città di Torino", Torino, Italy.
Andrea De VitoUnit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Giuseppe Vittorio De SocioInfectious Diseases Clinic, Department of Medicine and Surgery, Azienda Ospedaliera and University of Perugia, Santa Maria Hospital, Perugia, Italy.
Maria Vittoria CossuDepartment of Infectious Diseases, University of Milan, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Federica BarreraUnit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Maria MazzitelliInfectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.ORCID https://orcid.org/0000-0003-0263-0703
Silvia NozzaInfectious Disease Unit, Università Vita Salute San Raffaele, Milano, Italy.ORCID https://orcid.org/0000-0002-2673-2731
Giovanni GuaraldiDepartment of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0002-5724-3914
Emanuele FocàDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.ORCID https://orcid.org/0000-0003-4395-5379
GEPPO Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.

Indexed as

elderlyhepatitis b reactivationinjectablepolypharmacysafety

Identifiers

PMID41550694
PMCPMC12810048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.